Table 2.
Standardized mortality rates for AML patients receiving chemotherapy by age and for all AML patients by chemotherapy status, relative to the USA general population. Data are standardized mortality rates, with 95% confidence interval in parentheses.
| Groups | SMR cardiac-specific | P value | SMR overall | P value |
|---|---|---|---|---|
| Overall | 6.35 (5.89-6.82) | < 0.0001 | 95.80 (94.74-96.86) | < 0.0001 |
| Age | ||||
| 50-54 | 11.03 (7.91-14.15) | < 0.0001 | 144.13 (138.33-149.92) | < 0.0001 |
| 55-59 | 9.98 (7.74-12.23) | < 0.0001 | 107.54 (103.65-111.43) | < 0.0001 |
| 60-64 | 6.13 (4.82-7.44) | < 0.0001 | 77.76 (75.24-80.28) | < 0.0001 |
| 65-69 | 5.11 (4.16-6.05) | < 0.0001 | 55.80 (54.09-57.50) | < 0.0001 |
| 70-74 | 3.26 (2.66-3.86) | < 0.0001 | 37.61 (36.47-38.75) | < 0.0001 |
| 75-79 | 1.86 (1.48-2.24) | < 0.0001 | 24.13 (23.32-24.94) | < 0.0001 |
| 80-84 | 1.25 (0.95-1.56) | = 0.077 | 15.08 (14.43-15.73) | < 0.0001 |
| Treatment | ||||
| Chemotherapy | 2.26 (2.10-2.42) | < 0.0001 | 96.62 (95.57-97.67) | < 0.0001 |
| No chemotherapy | 5.53 (5.27-5.79) | < 0.0001 | 125.49 (124.24-126.73) | < 0.0001 |
Abbreviations: SMR: standardized mortality rates; AML: acute myeloid leukemia.